Sit A S, Price F V, Kelley J L, Comerci J T, Kunschner A J, Kanbour-Shakir A, Edwards R P
Division of Gynecologic Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, USA.
Gynecol Oncol. 2000 Nov;79(2):196-200. doi: 10.1006/gyno.2000.5956.
The aim of this study was to review the chemotherapy experience at Magee-Womens Hospital for malignant mixed müllerian tumor (MMMT) of the ovary. Patients were treated with either paclitaxel/carboplatin (PC) outpatient chemotherapy or platinum/ifosfamide (PI) inpatient chemotherapy as first- or second-line therapy.
Thirteen patients diagnosed with MMMT of the ovary after complete surgical staging from 1990 to 1999 were studied retrospectively. Six patients received PC combination chemotherapy, of which 3 patients received PC as first-line treatment. The other 3 patients received PC as second-line therapy. Eight patients were treated with PI. Demographic data, pathology, cytoreductive surgery, treatment, and survival rates were reviewed. Complete clinical response (CR) was defined as the disappearance of all measurable disease or normalization of elevated CA 125 level after chemotherapy. Kaplan-Meier analysis was used for survival analysis.
The median survival time of patients receiving PC was 19 months. One patient, after receiving PC as first-line treatment, demonstrated a CR and is free of disease beyond 33 months. The median survival time of patients managed with PI was 23 months. Three patients with suboptimal disease demonstrated CR after receiving PI.
Optimal chemotherapy regimen for MMMT of ovary remains to be determined. Platinum-based chemotherapy in combination with ifosfamide or paclitaxel may be active against this rare malignancy.
本研究旨在回顾梅杰妇女医院治疗卵巢恶性苗勒管混合瘤（MMMT）的化疗经验。患者接受紫杉醇/卡铂（PC）门诊化疗或铂/异环磷酰胺（PI）住院化疗作为一线或二线治疗。
回顾性研究1990年至1999年13例经完整手术分期后诊断为卵巢MMMT的患者。6例患者接受PC联合化疗，其中3例患者接受PC作为一线治疗。另外3例患者接受PC作为二线治疗。8例患者接受PI治疗。回顾人口统计学数据、病理、肿瘤细胞减灭术、治疗及生存率。完全临床缓解（CR）定义为化疗后所有可测量疾病消失或升高的CA 125水平恢复正常。采用Kaplan-Meier分析进行生存分析。
接受PC治疗的患者中位生存时间为19个月。1例接受PC一线治疗的患者出现CR，且疾病无进展超过33个月。接受PI治疗的患者中位生存时间为23个月。3例病情未达最佳状态的患者在接受PI治疗后出现CR。
卵巢MMMT的最佳化疗方案仍有待确定。以铂类为基础的化疗联合异环磷酰胺或紫杉醇可能对这种罕见的恶性肿瘤有效。
